Scarica l'app Stockscreener
0.2748
5.76%
-0.0168
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ITRM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.2916
Aprire:
$0.286
Volume 24 ore:
725.79K
Relative Volume:
0.87
Capitalizzazione di mercato:
$14.64M
Reddito:
-
Utile/perdita netta:
$-24.08M
Rapporto P/E:
-0.3206
EPS:
-0.8572
Flusso di cassa netto:
$-14.75M
1 W Prestazione:
-9.01%
1M Prestazione:
-18.21%
6M Prestazione:
-66.35%
1 anno Prestazione:
-81.68%
Intervallo 1D:
$0.2585
$0.307
Intervallo di 1 settimana:
$0.2585
$0.3165
Portata 52W:
$0.2585
$1.58
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Nome
Iterum Therapeutics Plc
Settore
Industria
Telefono
(872) 225-6077
Indirizzo
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.2748 | 15.54M | 0 | -24.08M | -14.75M | -0.8572 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Downgrade | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie
Iterum Therapeutics expands Medicare Part D access for ORLYNVAH By Investing.com - Investing.com Nigeria
Iterum Therapeutics Provides Business Update - Bitget
Iterum Therapeutics expands Medicare Part D access for ORLYNVAH - Investing.com
Iterum Therapeutics Announces Expanded Market Access and Patent Protection for ORLYNVAH™ - Quiver Quantitative
Medicare to cover ORLYNVAH for 3.5M people, but FDA seeks new trial - Stock Titan
Published on: 2026-02-12 20:05:19 - baoquankhu1.vn
Is Iterum Therapeutics plc’s ROIC above industry averageMarket Weekly Review & Risk Controlled Stock Pick Alerts - mfd.ru
Is Iterum Therapeutics plc stock forming a triangle patternDividend Hike & Low Volatility Stock Recommendations - mfd.ru
Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Friday - Defense World
Investment Review: What dividend growth rate does CTNT offerEarnings Trend Report & Low Risk High Reward Ideas - baoquankhu1.vn
Gap Down: Is UPSD stock a good pick for beginners2025 Key Highlights & Expert Approved Momentum Ideas - baoquankhu1.vn
Fed Meeting: How correlated is W R Berkley Corporation to the S P500July 2025 Gainers & Verified Swing Trading Watchlist - baoquankhu1.vn
ITRM Stock Price, Forecast & Analysis | ITERUM THERAPEUTICS PLC (NASDAQ:ITRM) - Chartmill
Portfolio Recap: Is Iterum Therapeutics plc stock risky to hold now2025 Earnings Impact & Community Trade Idea Sharing Platform - baoquankhu1.vn
Weekly Earnings: How does Hovnanian Enterprises Inc compare to its peersRate Cut & Real-Time Price Movement Reports - baoquankhu1.vn
Activity Recap: What are the future prospects of Iterum Therapeutics plcMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
Patterns Watch: Is Iterum Therapeutics plc stock a safe haven assetLayoff News & Low Risk Entry Point Tips - Bộ Nội Vụ
Will Iterum Therapeutics plc stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - Улправда
Is Iterum Therapeutics plc stock overvalued by current metricsProfit Target & High Return Trade Opportunity Guides - ulpravda.ru
Will Iterum Therapeutics plc stock benefit from sector rotationInflation Watch & Safe Capital Growth Stock Tips - Улправда
Can Iterum Therapeutics plc stock deliver surprise earnings beatWeekly Trade Report & Expert Curated Trade Setup Alerts - Улправда
Why Iterum Therapeutics plc stock remains a top recommendationStock Buyback Updates & Market Monitoring and Alerts - Улправда
Iterum Therapeutics expands market access for ORLYNVAH antibiotic - Investing.com
Iterum Therapeutics provides business update - marketscreener.com
New antibiotic ORLYNVAH could reach 34M+ people pending FDA feedback - Stock Titan
Analyzing Iterum Therapeutics (NASDAQ:ITRM) & Savara (NASDAQ:SVRA) - Defense World
Why hedge funds are buying Iterum Therapeutics plc stockWeekly Trade Analysis & Capital Efficient Trade Techniques - Улправда
Iterum Therapeutics secures major PBM agreement for antibiotic By Investing.com - Investing.com Nigeria
Iterum Therapeutics (ITRM) Secures Key PBM Agreement and Expands Patent Portfolio - GuruFocus
Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com
New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan
Iterum Therapeutics faces Nasdaq listing compliance challenge - MSN
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge - The Globe and Mail
Iterum Therapeutics receives Nasdaq notice on listing compliance By Investing.com - Investing.com Australia
Iterum Therapeutics plc Stock Analysis and ForecastEarnings Forecast Updates & Fast Profit Stock Ideas - earlytimes.in
Iterum Therapeutics receives Nasdaq notice on listing compliance - Investing.com
Iterum Therapeutics (NASDAQ: ITRM) discloses Nasdaq delisting risk on value, price - Stock Titan
Iterum Therapeutics Plc (ITRM) can make a big difference with a little luck - setenews.com
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH By Investing.com - Investing.com Nigeria
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH - Investing.com
ITRM Expands ORLYNVAH Access and Secures Key Medicare Part D Agr - GuruFocus
Iterum Therapeutics (Nasdaq: ITRM) inks Medicare Part D deal, EU patent to 2039 - Stock Titan
Iterum Therapeutics (ITRM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Taking on analysts’ expectations and winning: Iterum Therapeutics Plc (ITRM) - setenews.com
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Iterum’s antibiotic ORLYNVAH now available through McKesson By Investing.com - Investing.com Nigeria
Iterum’s antibiotic ORLYNVAH now available through McKesson - Investing.com
Iterum Therapeutics (ITRM) Expands Product Availability and FDA Clearance - GuruFocus
Iterum Therapeutics Plc Azioni (ITRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):